- Home
- Companies
- Kephera Diagnostics, LLC
- Products
- Covi-Quant - Covid-19 Quantitative ...
Covi-Quant - Covid-19 Quantitative Antibody Test
The COVI-QUANT™ test will give you an answer. It represents the latest generation of testing technology that will provide a numerical value for your antibody level, not just yes or no. COVI-QUANT™ is an ELISA test available through Kephera’s CLIA laboratory. Studies show that not all individuals develop a strong immune response after COVID-19 infection or vaccination, especially those who have an immunocompromising condition due to disease, medical treatment, organ transplantation, age, or other causes. These individuals may continue to be at risk of COVID-19 infection due to a weak immune response, which can be reflected in low antibody levels. Additionally, how long COVID-19 vaccines will protect even healthy people is unknown at this point. Monitoring antibody levels over a period of months or years can provide a way to gauge the strength of the immune response as it changes.
Detect
The COVI-QUANT™ test detects antibodies to the Spike protein - the major component of all COVID-19 vaccines. The COVI-QUANT™ test is an Enzyme-Linked Immunosorbent Assay (ELISA) that detects antibodies against the spike protein, which is a major feature of the SARS-CoV-2 virus and the main component in all COVID-19 vaccines. Many other antibody tests on the market target proteins that may not be used in vaccines.
Measure
The COVI-QUANT™ test measures antibody levels in WHO international standard units. Kephera’s COVI-QUANT™ test is a quantitative test that measures the level of antibody in your blood after COVID-19 infection or vaccination. The COVI-QUANT™ test yields a numerical value for your antibody level. This differs from other antibody tests that may only provide you with a positive/negative result.
Kephera’s COVI-QUANT™ test is calibrated to the World Health Organization (WHO) standard1. You will receive your COVI-QUANT™ results in Binding Antibody Units (BAU/ml), the international standard established by the WHO.
Compare
Antibody levels vary across people: The COVI-QUANT™ test allows you to compare your level to others
Most people will develop antibodies within several weeks after receiving a COVID-19 vaccine or after being infected with the virus. The strength of your immune response to vaccination or infection is determined by many factors including your age, health, and pre-existing conditions2,3,4.
The COVI-QUANT™ test will tell you your antibody level, and how it compares with the levels of others who have been vaccinated or infected. The graph shows antibody levels measured using COVI-QUANT™ in vaccinated and infected individuals, and highlights the variability in levels between individuals and between the two groups. Some infected or vaccinated people show very low or undetectable levels of antibodies.
Higher levels of antibody reflect a stronger immune response, and vice-versa. The exact relationship between antibody levels and degree of immunity to COVID-19 infection is still being researched.
Track
Antibody levels can rise or fall: The COVI-QUANT™ test allows you to track your level over time
It is not yet clear how long antibodies continue to circulate in people who have been vaccinated or infected, and how long vaccine immunity lasts. Some studies show that antibody levels after vaccination or infection decrease over time5,6.
The graph shows the change in antibody levels measured by COVI-QUANT™ in an individual who was tested at successive time points after COVID-19 vaccination.
Tracking changes in your immune response over the months that follow vaccination or infection can assist you and your healthcare provider in evaluating your ongoing COVID-19 infection risk.
Correlate
Antibodies typically protect you from infection. Neutralization refers to the ability of antibodies to block the binding of the SARS-CoV-2 virus to the human receptor, and neutralization activity is associated with protection7. It is not yet known what level of antibodies is needed to protect an individual from COVID-19 infection, but higher levels are likely to confer greater protection and vice-versa.
The COVI-QUANTTM test shows strong agreement with an FDA-approved neutralization test. Samples with low antibody levels as measured by the COVI-QUANT™ test showed low levels of neutralization, while samples with high levels of antibodies showed high neutralization activity.